West Chester, OH, United States of America

Angelique Sun Boyer

This inventor holds 15 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Akebia Therapeutics, Inc., Warner Chilcott Company, LLC, Kreos Capital VII (UK) Limited. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Angelique Sun Boyer. Retrieved from https://idiyas.com/inventor/angelique-sun-boyer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 6.0

ph-index = 10

Forward Citations = 308(Granted Patents)

Company Filing History:

11 out of 38

Akebia Therapeutics, Inc.

patents

2 out of 39

Warner Chilcott Company, LLC

patents

1 out of 2

Kreos Capital VII (UK) Limited

patents

4. 1 out of 17,173

The Procter Gamble Company

patents

Years Active: 2009-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12478615 - PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE (2025-11-25),

2. 11883386 - Prolyl hydroxylase inhibitors and methods of use (2024-01-30),

3. 11426393 - Prolyl hydroxylase inhibitors and methods of use (2022-08-30),

4. 10729681 - Prolyl hydroxylase inhibitors and methods of use (2020-08-04),

5. RE47437 - Prolyl hydroxylase inhibitors and methods of use (2019-06-17),

6. 9598370 - Prolyl hydroxylase inhibitors and methods of use (2017-03-21),

7. 8940773 - Prolyl hydroxylase inhibitors and methods of use (2015-01-27),

8. 8722895 - Prolyl hydroxylase inhibitors and method of use (2014-05-13),

9. 8598210 - Prolyl hydroxylase inhibitors and methods of use (2013-12-03),

10. 8512972 - Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase (2013-08-20),

11. 8343952 - Prolyl hydroxylase inhibitors and methods of use (2013-01-01),

12. 8323671 - Prolyl hydroxylase inhibitors and methods of use (2012-12-04),

13. 8050873 - Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase (2011-11-01),

14. 7811595 - Prolyl hydroxylase inhibitors and methods of use (2010-10-12),

15. 7588924 - Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase (2009-09-15),

Title: **Angelique Sun Boyer: Innovator in Prolyl Hydroxylase Inhibitors**

Introduction

Angelique Sun Boyer is a notable inventor residing in West Chester, OH, renowned for her significant contributions to the field of biomedical research. With a total of 14 patents to her name, she has demonstrated a commitment to advancing medical technologies and therapies that have crucial implications for various health conditions.

Latest Patents

Among her recent patents, Angelique has developed methods and compositions related to prolyl hydroxylase inhibitors. These inventions focus on HIF-1α prolyl hydroxylase inhibitors and address conditions such as Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. The innovative approaches outlined in her patents have the potential to transform treatment strategies for these serious health conditions.

Career Highlights

Angelique has had an impressive career, contributing her expertise to companies like Akebia Therapeutics, Inc. and Warner Chilcott Company, LLC. Her work at these organizations has been instrumental in pushing the boundaries of therapeutic innovations and improving patient outcomes.

Collaborations

Throughout her career, Angelique has collaborated with esteemed professionals, including Artem G. Evdokimov and Richard Masaru Kawamoto. These partnerships highlight the importance of teamwork in scientific advancements and the collective efforts made toward impactful research.

Conclusion

Angelique Sun Boyer's work exemplifies the spirit of innovation in the medical field. Her expertise and dedication to developing prolyl hydroxylase inhibitors showcase her role as a leading inventor, committed to addressing critical health challenges through her inventions. As she continues her research, her contributions are likely to play a significant role in shaping the future of biomedical treatments.

Profile summary based on public USPTO records.